{"denoms":[{"counts":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"351"}],"units":"Participants"}],"groups":[{"description":"Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.\n\nDexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.","id":"BG000","title":"Lenalidomide Plus Dexamethasone"},{"description":"Placebo PO daily on Days 1 to 28 of each 28 day cycle.\n\nDexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.","id":"BG001","title":"Placebo Plus Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.12","value":"62.2"},{"groupId":"BG001","spread":"8.80","value":"62.9"},{"groupId":"BG002","spread":"9.47","value":"62.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"144"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"207"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"143"}]}],"title":"0 = (Fully Active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"151"}]}],"title":"1 = (Restrictive but Ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"50"}]}],"title":"2 = Ambulatory unable to Work)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"3 = (Limited Self-Care)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"4 = (Completely Disabled)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Missing"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants' disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"113"}]}],"title":"1 Prior anti-myeloma therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"238"}]}],"title":"2 or more prior anti-myeloma therapies"}],"paramType":"NUMBER","title":"Number of Prior Anti-Myeloma Therapies","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.4","upperLimit":"15.7","value":"3.4"},{"groupId":"BG001","lowerLimit":"0.3","upperLimit":"26.6","value":"4.0"},{"groupId":"BG002","lowerLimit":"0.3","upperLimit":"26.6","value":"3.7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time from First Pathological Diagnosis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"107"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"225"}]}],"title":"Stage III"}],"description":"The International Staging System divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels.\n\nStage I: Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L);\n\nStage II: Neither stage I or III, meaning that either:\n\n* The beta-2 microglobulin level is between 3.5 and 5.5 (with any albumin level), OR\n* The albumin is below 3.5 while the beta-2 microglobulin is less than 3.5\n\nStage III: Serum beta-2 microglobulin is greater than 5.5.","paramType":"NUMBER","title":"Baseline multiple myeloma stage","unitOfMeasure":"participants"}],"populationDescription":"Intent to treat population included all participants who were randomized"}